NCT06177015View on ClinicalTrials.gov

Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC

PHASE3RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

December 11, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
Metastatic Prostate CancerIntermitent Anti-androgen Therapy
Interventions
DRUG

Darolutamide continuous

standard of care

DRUG

Darolutamide intermittent

experimental group

Trial Locations (1)

210029

RECRUITING

Urology dpt, First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER